759P Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer

Authors :: A. Khorau
E. Zhavrid
O. Sergeeva
S. Kozlovskaya
S. Polyakov
A. Shneider
K. Zharkova
V. Gabai
Y. Baranau
S. Krasny
Source :: Annals of Oncology. 32:S747-S748
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Chemotherapy
business.industry
medicine.medical_treatment
Hematology
medicine.disease
Gemcitabine
Plasmid
Oncology
Cancer research
Medicine
Dosing
business
Ovarian cancer
Platinum resistant
medicine.drug

Full Text Access

Tools